Non-FDG imaging of atherosclerosis: Will imaging of MMPs assess plaque vulnerability?

Journal of Nuclear Cardiology

Volumn 19, Issue 3, 2012, Pages 609-617

  Hermann, Sven ^a   Starsichova, Andrea ^a   Waschkau, Bianca ^a   Kuhlmann, Michael ^a   Wenning, Christian ^b   Schober, Otmar ^b   Schäfers, Michael ^a,b  

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Atherosclerosis; Imaging; MMP; PET; Plaque; Vulnerability

Indexed keywords

CARBON 11; COLLAGENASE 3; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GADOTERIC ACID; GELATINASE A; GELATINASE B; INDIUM 111; INTERSTITIAL COLLAGENASE; IODINE 123; IODINE 124; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE RUPTURE; BLOOD VESSEL OCCLUSION; BLOOD VESSEL RUPTURE; BLOOD VESSEL WALL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; HEART INFARCTION; HUMAN; INFLAMMATION; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL PROCESSING; STROKE;

ANIMALS; ATHEROSCLEROSIS; FLUORODEOXYGLUCOSE F18; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84864060488     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9553-6     Document Type: Review

References (48)

1. Ross R. Atherosclerosis\an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. (Pubitemid 36019640)
3. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 2003;2004:1077-82.
4. Yla-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 2011;106:1-19.
5. Schwartz RG. Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve. J Nucl Cardiol 2010;17:985-9.
6. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American heart association. Circulation 1995;92: 1355-74.
7. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003;349:2316-25. (Pubitemid 37509739)
8. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, et al. The thin-cap fibroatheroma: A type of vulnerable plaque: The major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001;16:285-92. (Pubitemid 32953605)
9. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503. (Pubitemid 24379627)
10. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apoli-poprotein E. Science 1992;258:468-71.
11. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994;93:1885-93. (Pubitemid 24143065)
12. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: Model characterization and effects of pravastatin treatment. Circulation 2005;111:1422-30. (Pubitemid 40396809)
13. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 2000;20:2587-92.
14. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002;22:788-92. (Pubitemid 34517790)
15. Sasaki T, Kuzuya M, Nakamura K, Cheng XW, Shibata T, Sato K, et al. A simple method of plaque rupture induction in apolipo-protein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26:1304-9. (Pubitemid 44305374)
16. Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH, et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 2005;111:3457-64. (Pubitemid 40923400)
17. Ni M, Chen WQ, Zhang Y.Animal models and potential mechanisms of plaque destabilisation and disruption. Heart 2009;95:1393-8.
18. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: A new observation. Clin Nucl Med 2001;26:314-9. (Pubitemid 32226294)
19. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with 18F-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11. (Pubitemid 34615139)
20. Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 2005;36:2642-7.
21. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation inpatients. J Am Coll Cardiol 2006;48:1818-24. (Pubitemid 44648622)
22. Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107-15.
23. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-6. (Pubitemid 47268746)
24. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563-8.
25. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet 2011;378:1547-59.
26. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neo-plastic disease. J Nucl Med 2009;50:1611-20.
27. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol 2011;58:603-14.
28. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011;278:28-45.
29. Wagner S, Breyholz HJ, Faust A, Holtke C, Levkau B, Schober O, et al. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 2006;13:2819-38. (Pubitemid 44509727)
30. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614-24. (Pubitemid 43140745)
31. Newby AC. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr Opin Lipidol 2006;17:556-61. (Pubitemid 44372687)
32. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346-55. (Pubitemid 32663965)
33. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: Involvement of macrophage migration and apoptosis. Circulation 2006;113: 2435-44. (Pubitemid 43948051)
34. Zheng QH, Fei X, DeGrado TR, Wang JQ, Stone KL, Martinez TD, et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-4-(6-fluorohex-1-ynyl) phenylsulfonylamino-3-methylbutyric acid 11Cmethyl ester. Nucl Med Biol 2003;30:753-60. (Pubitemid 37123133)
35. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003;30:119-25. (Pubitemid 36293712)
36. Sahul ZH, Mukherjee R, Song J, McAteer J, Stroud RE, Dione DP, et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: Relationship to myocardial dysfunction. Circ Car-diovasc Imaging 2011;4:381-91.
37. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005;112:3157-67.
38. Breyholz HJ, Wagner S, Faust A, Riemann B, Holtke C, Hermann S, et al. Radiofluorinated pyrimidine-2, 4, 6-triones as molecular probes for noninvasive MMP-targeted imaging. Chem Med Chem 2010;5:777-89.
39. Faust A, Waschkau B, Waldeck J, Holtke C, Breyholz HJ, Wagner S, et al. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases. Bioconjug Chem 2009;20:904-12.
40. Wagner S, Breyholz HJ, Holtke C, Faust A, Schober O, Schäfers M, et al. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies. Appl Radiat Isot 2009;67:606-10.
41. Schäfers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schäfers KP, et al. Scintigraphic imaging of matrix metallopro-teinase activity in the arterial wall in vivo. Circulation 2004; 109:2554-9. (Pubitemid 38720556)
42. Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008;118:1953-60.
43. Hartung D, Schäfers M, Fujimoto S, Levkau B, Narula N, Kopka K, et al. Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. Eur J Nucl Med Mol Imaging 2007;34:S1-8. (Pubitemid 46956016)
44. Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yala-manchili P, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: Resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008;52:1847-57.
45. Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med 2011;52:1795-802.
46. Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 2008;28:425-32.
47. Azhdarinia A, Wilganowski N, Robinson H, Ghosh P, Kwon S, Lazard ZW, et al. Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide. Bioorg Med Chem 2011;19:3769-76.
48. Wagner S, Faust A, Breyholz HJ, Schober O, Schäfers M, Kopka K. The MMP inhibitor (R)-2-(N-benzyl-4-(2-18Ffluoroeth-oxy)phenylsulphonamido)-N- hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. Appl Radiat Isot 2011;69:862-8.